ABOUT
Overview
Dr. Evan Cole Lewis is a Neurologist and Clinical Neurophysiologist with expertise in pediatric neurology and epilepsy. He is an Assistant Professor with the Department of Pediatrics at the Hospital for Sick Children and the University of Toronto.
Dr. Lewis is the founder & medical director of the Neurology Centre of Toronto (NCT), Chief Medical Advisor for the Jamaican Medical Cannabis Corporation and VP Psychedelic Neurology at Numinus – a Canadian company focused on research and therapeutics with psychedelic medicines.
Dr. Lewis has clinical experience and special interest with psychedelic medicine and medical cannabis in the treatment of neurological conditions in adults and children. He is a strong advocate for the use of virtual medicine to reach the underserved areas of Ontario, Canada.
Education, Training & Work
Dr. Lewis attained his MD from the University of Ottawa and trained as a Pediatric Neurologist at the Children’s Hospital of Eastern Ontario (CHEO). He completed fellowships in both clinical neurophysiology and epilepsy at Nicklaus Children’s Hospital (formerly known as Miami Children’s Hospital) and the Hospital for Sick Children. Dr. Lewis held staff positions at SickKids and Holland Bloorview Kids Rehabilitation Hospital between 2016 and 2018.
Work in Medical Cannabis
Dr. Lewis has significant clinical experience with medical cannabis in adults and children and is a member of the Canadian Consortium for the Investigation of Cannabinoids (CCIC), the Cannabinoid Research Initiative of Saskatchewan (CRIS) and the Canadian Childhood Cannabinoid Clinical Trials (C4T) group. He is a qualified investigator and site lead for a clinical trial in cannabis treatment of chronic headache in adolescents that is set to begin in the winter of 2023. Dr. Lewis is the Chief Medical Adviser for the Jamaican Medical Cannabis Corporation. In the United Kingdom, he is member of the Expert Committee of the Medical Cannabis Clinicians Society (MCCS) and an advisor for the Medical Cannabis Working Group for Drug Science, Intractable Epilepsy charity, Cannabis Patient Advocacy & Support Services (CPASS) and MedCan. He has spoken extensively on cannabis in neurologic disorders nationally and internationally.
Work in Psychedelic Medicines
Dr. Lewis focuses on indications, treatment and novel approaches of psychedelic medicines. He has clinical experience treating and counselling patients with underlying neurologic conditions who have utilized psychedelics such as psilocybin, MDMA and ketamine. As medical director of NCT, he has special interest in utilizing ketamine-assisted therapy as adjunct treatment for functional neurological disorders, persistent post-concussive symptoms and co-morbid mental health conditions that arise from neurologic diagnoses. He has delivered educational seminars, talks and lectures on psychedelics and the intersection of psychedelics in neurology both locally and internationally.
Postions & Research
Dr. Lewis is a Fellow of the Royal College of Physicians of Canada and was the Tariff Chair of the Neurology Section for the Ontario Medical Association from 2017 - 2019. He sits on the Editorial Board for the Journal of Child Neurology’s Resident/Fellow Section and is a reviewer for the Canadian Journal of Neurological Sciences, Paediatrics & Child Health, Epilepsy & Behaviour and the NIHR in the UK. His research interests include psychedelic neurology, cannabinoids in the treatment of epilepsy & other neurological conditions and the delivery of novel virtual care models in neurology. His special clinical interests include functional neurological disorders and treatment of chronic symptoms of TBI.
Publications:
Link to Publications: https://goo.gl/yLhvN1